Platelet‐activating factor in stroke and brain injury

Annals of Neurology

Volumn 30, Issue 2, 1991, Pages 117-129

  Lindsberg, Perttu J ^a   Hallenbeck, John M ^a   Feuerstein, Giora ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOTRIENE; PHOSPHATIDYLINOSITIDE; PHOSPHOLIPASE C; PROSTACYCLIN; THROMBOXANE A2;

BRAIN EDEMA; BRAIN INJURY; BRAIN VASOSPASM; CEREBROVASCULAR DISEASE; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE;

ANIMAL; BRAIN INJURIES; BRAIN ISCHEMIA; HUMAN; PLATELET ACTIVATING FACTOR;

EID: 0025738206     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.410300202     Document Type: Article

References (104)

1. Perspectives in platelet‐activating factor research
2. Sirén A‐LPlatelet activating factor and shock
3. Three forms of PAF in normal rat tissues
4. Leukocytedependent histamine release from rabbit platelets: the role of IgE, basophils, and a platelet‐activating factor
5. Cellular origin of PAF
6. Biphasic platelet‐activating factor synthesis by human monocytes stimulated with IL‐β, tumor necrosis factor, or IFN‐γ
7. Human endothelial cells in culture produce platelet‐activating factor (1‐alky1‐2‐acetyl‐sn‐glyceryl‐3‐phosphocholine) when stimulated with thrombin
8. Endothelium from diverse vascular sources synthesizes platelet‐activating factor
9. Interleukin‐1 stimulates platelet‐activating factor production in cultured human endothelial cells
10. Synthesis and release of platelet‐activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin‐1
11. Prostacyclin synthesis induced in vascular cells by interleukin‐1
12. Platelet‐activating factor (PAF‐acether) secretion from platelets: effect of aggregating agents
13. Production of platelet‐activating factor by chick retina
14. Production of platelet‐activating factor from rat cerebellar granule cells in culture
15. Alkaline O→N transacylation
16. Biochemistry of platelet‐activating factor: a unique class of biologically active phospholipids
17. Platelet‐activating factor
18. A new de novo pathway for the formation of 1‐alkyl‐sn‐glycerols, precursors of platelet‐activating factor
19. Formation of 1‐alkyl‐2‐acetyl‐sn‐glycerols via the de novo biosynthetic pathway for platelet‐activating factor
20. The de novo biosynthesis of platelet‐activating factor in rat brain
21. Rapid production of diacylglycerols enriched in arachidonate and stearate during early brain ischemia
22. Enzymatic synthetic analysis of 1‐alkyl‐2‐acetyl‐sn‐glycero‐3‐phosphocholine, a hypotensive and platelet‐aggregating lipid
23. Human plasma platelet‐activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet‐activating factor
24. A specific acetylhydrolase for 1‐alkyl‐2‐acetyl‐sn‐glycero‐3‐phosphocholine (a hypotensive and platelet‐activating lipid)
25. The potential role of the PAF acetyl‐hydrolase in human disease
26. Activity of platelet‐activating factor (PAF) acetylhydrolase in plasma from patients with ischemic cerebrovascular disease
27. Physicochemical and functional identity of rabbit platelet‐activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils
28. Release of platelet‐activating factor in systemic lupus erythematosus
29. Polymorphonuclear leucocyte accumulation in brain regions with low blood flow during the early postischemic period
30. Platelet accumulation in regions of low blood flow during the postischemic period
31. Subcellular localization of phospholipids and enzymes involved in PAF‐acether metabolism
32. Regulation of the synthesis of platelet‐activating factor and its inactive storage precursor (1‐alkyl‐2‐acyl‐sn‐glycero‐3‐phosphocholine) from 1‐alkyl‐2‐acetyl‐sn‐glycerol by rabbit platelets
33. Leukocyte‐platelet interaction in inflammation
34. Evidence of various homologues and analogues of platelet‐activating factor in a lipid extract of bovine brain
35. Production and effects of platelet‐activating factor in the rat brain
36. Deteriorating stroke model: histopathology, edema, and eicosanoid changes following spinal cord ischemia in rabbits
37. Evidence of platelet‐activating factor as a novel mediator in experimental stroke in rabbits
38. Neuroregulatory and neuropathological actions of the ether‐phospholipid platelet‐activating factor
39. Platelet‐activating factor stimulates a Fos/Jun/AP‐1 transcriptional signaling system in human neuroblastoma cells
40. Mapping patterns of c‐fos expression in the central nervous system after seizure
41. Proto‐oncogene c‐fos transient ly induced in the rat cerebral cortex after forebrain ischemia
42. Platelet‐activating factor is a general membrane perturbant
43. Presence of specific binding sites for platelet‐activating factor (PAF) in brain
44. Distinct platelet‐activating facotr binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex
45. Cloning by functional expression of platelet‐activating factor receptor from guineapig lung
46. A randomized trial comparing ticlopidine hydrochloride with aspirin for prevention of stroke in high‐risk patients
47. Aggregation of human platelets by platelet‐activating factor
48. Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin or A23187
49. The role of platelet‐activating factor in platelet aggregation
50. The effect of 1‐O‐alkyl‐2‐acetyl‐sn‐glycero‐3‐phosphocholine (PAF‐acether) on the arterial wall
51. PAF‐acether antagonists in experimental arterial thrombosis
52. A PAF‐acether antagonist (N 48740/RP) and laser‐induced thrombi in rat mesenteric vessels
53. Role of platelet‐activating factor in primary hemostasis
54. Stimulus‐response coupling in human platelets. Evidence against a role of PAF‐acether in the “third pathway
55. Indućtion of leukocytic infiltrates in rabbit skin by acetyl glyceryl ether phosphorylcholine
56. Acute microvascular effects of PAF‐acether, as studied by intravital microscopy
57. Morphologic basis of increased vascular permeability induced by acetyl glyceryl ether phosphorylcholine
58. 1‐O‐alkyl‐sn‐glyceryl‐3‐phosphorylcholines: a novel class of neutrophil stimulants
59. Activation of human neutrophils with 1‐O‐hexadecyl/octadecyl‐2‐acetyl‐sn‐glyceryl‐3‐phosphorylcholine (platelet‐activating factor)
60. Plateletactivating factor primes neutrophil responses to agonists: role in promoting neutrophil‐mediated endothelial damage
61. Neutrophil‐mediated vascular injury
62. Platelet‐activating factor‐induced microvascular dysfunction: role of adherent leukocytes
63. Platelet‐activating factor‐induced hydrolysis of phosphatidylinositol 4,5‐biphosphate stimulates the production of reactive oxygen intermediates in macrophages
64. Effect of platelet‐activating factor (PAF‐acether) and its specific receptor antagonist, BN 52021, on interleukin 1 (ILl) release and synthesis by rat spleen adherent monocytes
65. Enhanced human monocyte cytotoxicity by platelet‐activating factor
66. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet‐activating factor
67. Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro
68. Endothelial cell‐associated platelet‐activating factor: a novel mechanism for signaling intercellular adhesion
69. Endogenous platelet‐activating factor does not modulate blood flow and metabolism in normal rat brain
70. Prostanoids determine the range of cerebral blood flow autoregulation of newborn piglets
71. Actions of platelet‐activating factor on isolated feline and human cerebral arteries
72. Platelet‐activating has no direct effect on rat intracerebral arterioles in vitro
73. Platelet activating factor: a potent constrictor of cerebral arterioles in new‐born pigs
74. Cerebrovascular and cerebrometabolic effects of intracarotid infused platelet activating factor in rats
75. Effect of systemic PAF‐acether on the spinal cord microcirculation
76. Effects of Gingko biloba on changes induced by quantitative cerebral microembolization in rats
77. Le Ginkgolide B (BN 52021): un puissant inhibiteur du PAF‐acether isolé du Ginkgo biloba
78. Involvement of platelet‐activating factor (PAF) in cerebral post‐ischemic phase in mongolian gerbils
79. Effects of platelet activating factor antagonist (BN 52021) on free fatty acids, diacylglycerols, polyphosphoinositodes and blood flow in the gerbil brain: inhibition of ischemia‐reperfusion induced cerebral injury
80. Platelet‐activating factor antagonist BN52021 decreases accumulation of free polyunsaturated fatty acid in mouse brain during ischemia and electroconvulsive shock
81. PAF antagonist gingkolide B reduces postischemic neuronal damage in rat brain hippocampus
82. Pharmacological profile of BN 50739, a new PAF‐antagonist in vitro and in vivo
83. Platelet activating factor receptor blockade enhances recovery after multifocal brain ischemia
84. Cortical microcirculation in a new model of focal laser‐induced secondary brain damage
85. Platelet‐activating factor antagonist protective in progressive focal brain damage
86. Antagonists reduce infarct size in focal ischemia in the rat brain
87. Blockade of N‐methyl‐D‐aspartate receptors may protect against ischemic damage in the brain
88. Morphometric evaluation of postischemic capillary perfusion in selectively vulnerable areas of gerbil brain
89. 2) on neutropenia induced by intravenous injection of platelet‐activating‐factor (PAF) in the rabbit
90. Acute circulatory collapse caused by platelet‐activating factor (PAF‐acether) in dogs
91. Effect of prostacyclin on platelet‐activating induced rabbit platelet aggregation
92. The effect of incomplete cerebral ischemia on prostaglandin levels in rat brain
93. Background review and current initiatives in reperfusion injury
94. Fatal ischaemic brain oedema after early thrombolysis with tissue plasminogen activator in acute stroke
95. Mediators of blood‐brain barrier dysfunction and formation of vasogenic brain edema
96. Influence of granulocytopenia on canine cerebral ischemia induced by air embolism
97. Inhibition of mononuclear phagocytes reduces ischemic injury in the spinal cord
98. Reduction of CNS reperfusion injury using neutrophil adhesion antibody treatment
99. The regulation of natural anticoagulant pathways
100. Interleukin‐1 induces endothelial cell procoagulant while suppressing cell surface anticoagulant activity
101. Adrenaline and PAF‐acether synergize to trigger cyclo‐oxygenase‐independent activation of plasma‐free human platelets
102. Preclinical and clinical pharmacology of platelet‐activating factor receptor antagonists
103. Effect of platelet‐activating factor (PAF) on blood flow distribution in the spontaneously hypertensive rat
104. Effect of an extract of Gingko biloba on rat brain energy metabolism in hypoxia